FGFR2 and hepatocellular carcinoma: FGFR2 downregulation has also been reported in bladder cancer [6] and in subtypes of hepatocellular carcinoma (HCC) [7], whereas in other cancer types/subtypes with overexpression of the FGFR2, including gastric cancer [8,9], triple negative breast cancer [10] and osteosarcoma [11], inhibition of the receptor decreases cancer cell proliferation and cell survival in vitro.